AI Applications in the Drug Development Pipeline

Bringing a new drug to market is a lengthy, resource-intensive process. AI is being applied across drug development to support data analysis and decision-making, including after a candidate has been identified. Its value and evidentiary weight depend on the model’s context of use, the quality and representativeness of its data, and an application-specific credibility assessment. This report examines AI applications in preclinical testing, clinical trial design and execution, regulatory submissions, and manufacturing scale-up, as well as their potential public-health implications. FDA’s January 2025 draft guidance describes a risk-based approach for AI models intended to support regulatory decisions on drug and biological-product safety, effectiveness, or quality.

Once a promising drug candidate is identified, it must undergo preclinical testing to evaluate safety, efficacy, and pharmacokinetics in laboratory and animal models before human trials. This stage, spanning in vitro experiments and animal studies, often takes several years and can be a bottleneck in development. AI technologies are now expediting preclinical research in several ways:

• Predictive Toxicology and Pharmacology:Machine learning models can analyze large datasets of chemical structures and biological assay results to predict a compound’s toxicity, off-target effects, and ADME (absorption, distribution, metabolism, excretion) properties in silico. By flagging candidates for further assessment early, AI models may help prioritize experiments, including some nonclinical studies; the evidence needed depends on the model's context of use. The U.S. FDA’s January 2025 draft guidance provides non-binding recommendations for establishing the credibility of an AI model for its specific context of use. The agency said the draft was informed by more than 800 external comments and its experience with more than 500 drug and biological-product submissions containing AI components since 2016. For example, AI algorithms have been trained to forecast cardiac or liver toxicity risk based on molecular structure and historical drug failures, allowing researchers to avoid compounds likely to cause harm. Likewise, AI-driven pharmacokinetic models can simulate drug behavior in virtual patients, helping to optimize dosing strategies before live animal testing.

• Digital Twins and Organs-on-Chips: Advanced New Approach Methodologies (NAMs), such as microphysiological systems (organ-on-chip models) and virtual “digital twin” simulations, are being enhanced by AI to replicate human biology more accurately than traditional animal models. These systems can model aspects of human organ responses to a drug and may complement other nonclinical evidence. Their suitability depends on the question, the technology’s validation, and the context of use; they are not a general replacement for animal or other nonclinical evidence. FDA’s draft guidance on new approach methodologies similarly emphasizes a science- and risk-based assessment of a methodology’s fitness for purpose.

• High-Throughput Screening and Lead Optimization: AI-driven tools greatly speed up the “design–make–test” cycle of lead optimization. Platforms like Insilico Medicine’s Pharma.AI and Atomwise’s AtomNet use deep learning to predict biological activity and prioritize the most promising analogues of a drug candidate for synthesis. This focused approach means fewer compounds need to be physically tested to arrive at a viable lead, cutting down experimental iterations. AI-enabled screening and medicinal-chemistry tools can prioritize compounds for experimental testing, but the resulting time and cost savings depend on the target, data quality, assay strategy, and validation work required. BenevolentAI’s platform, for example, rapidly analyzes vast chemistry and genomic datasets to suggest optimal modifications to improve a molecule’s efficacy and safety, streamlining the preclinical lead refinement.

The Impact Of Fdas Animal Use Shift On The Future Of Preclinical Testing - genengnews.com

AI-driven digital models are increasingly used in preclinical research. By integrating lab data with computational simulations (“digital twins”) of human biology, researchers can predict a drug’s safety and efficacy profiles much faster than with traditional animal testing. Such approaches aim to reduce reliance on animal models while accelerating the path to first-in-human trials.

Early clinical evidence: Rentosertib is an AI-generated TNIK inhibitor being studied for idiopathic pulmonary fibrosis. In a 71-participant, 12-week Phase IIa trial, the primary endpoint was treatment-emergent adverse events. The 60 mg once-daily group had a mean FVC change of +98.4 mL (95% CI, 10.9 to 185.9), compared with −20.3 mL (95% CI, −116.1 to 75.6) with placebo; FVC was a secondary endpoint. However, 16 of 71 participants discontinued treatment before week 12, and seven discontinuations for adverse events were due to liver injury or dysfunction. The study authors concluded that larger, longer trials are needed. This early signal does not establish clinical efficacy or validate AI discovery as a general drug-development paradigm. Study details Meanwhile, Exscientia became a wholly owned subsidiary of Recursion Pharmaceuticals when the companies’ business combination was completed in November 2024. The combined company has described its platform as intended to accelerate discovery, but company-reported candidate-design timelines are not general comparisons with conventional development. AI-enabled tools can prioritize hypotheses and experiments in preclinical research; whether they shorten an end-to-end program, reduce attrition, or improve later-stage clinical success depends on the specific application, evidence base, and validation. Recursion announcement FDA draft guidance

Clinical trials are traditionally the longest phase of drug development, often spanning 6–8 years across Phase I, II, and III for a new drug. They involve complex protocol design, patient recruitment, data collection, and analysis processes. AI is now being deployed across the clinical trial lifecycle to accelerate trial startup, improve patient enrollment, streamline data handling, and enable faster decision-making. Key applications include:

• Protocol Design and Trial Planning: Developing a clinical trial protocol (the study plan) is a labor-intensive process requiring analysis of prior trials and input from medical experts. AI tools, particularly natural language processing (NLP) and large language models (LLMs), can significantly speed up this step. For example, AI copilots can review thousands of pages of medical literature, past trial results, and regulatory guidelines in a short time, then auto-generate a draft protocol or key protocol elements. AI can help teams retrieve and organize relevant information and prepare draft protocol content, but sponsors remain responsible for expert review and for establishing that any tool is fit for its intended use. FDA’s AI-model draft guidance does not cover AI used solely for operational efficiencies, such as drafting or writing a regulatory submission, when that use does not affect patient safety, product quality, or the reliability of nonclinical or clinical-study results. FDA draft guidance AI can also simulate trial outcomes during planning: machine learning models predict likely success rates or identify risky aspects of a trial design (e.g. endpoints that historically correlate with failure), allowing teams to optimize the design before launch. Notably, AI has even been used to generate smarter eligibility criteria – tools like TrialGPT analyze disease characteristics and suggest inclusion/exclusion criteria that widen the pool of eligible patients without sacrificing safety. These tools may support protocol development, but their effect on trial timelines, trial quality, endpoints, dosing decisions, or patient selection has to be established for the intended use and study context.

• Site Selection and Patient Recruitment: Finding and enrolling patients is often the rate-limiting step of clinical trials – roughly 80–90% of trials experience delays in recruitment and many fail to meet enrollment targets. AI is tackling this challenge by analyzing real-world data (such as electronic health records, insurance claims, and patient registries) to identify eligible patients and optimal trial sites much faster. For example, AI-based platforms can automatically scan electronic medical records to match patients to trial criteria in minutes, a task that previously took trial coordinators many hours per patient. AI-assisted screening may reduce manual record-review work, but its accuracy, operational burden, cost, and effect on enrollment should be evaluated for the intended population, data source, and workflow. On the site selection side, AI models evaluate hospitals and clinics to predict which sites will recruit effectively (based on factors like patient demographics, past performance, and physician referral networks). Selecting high-performing sites upfront means trials can enroll to full capacity faster. While early AI engines for site selection performed on par with humans ^[1], improvements in training data are boosting their accuracy. By picking better sites and focusing investigator outreach, sponsors avoid the common pitfall of under-enrolling centers that slow trials ^[2]. AI-assisted recruitment and site-selection tools may help identify potentially eligible participants and feasible sites, but their performance, cost effect, and effect on enrollment must be demonstrated for the individual trial and data source. AI-generated prognostic scores may be used as covariates to improve precision in a randomized trial when the method is appropriately validated for its specified context of use. EMA issued a 2022 qualification opinion for PROCOVA, a prognostic-covariate-adjustment methodology. That opinion concerns its specified context of use; it is not a general authorization for Phase II or III primary analyses and does not establish FDA concurrence. EMA qualification materials In a 2025 Alzheimer's & Dementia publication, Unlearn demonstrated that AI-generated digital twins can reduce variance in treatment effect estimates across all outcomes in real Phase 2 Alzheimer's trials. Similarly, Accenture's strategic investment in Ryght AI in late 2025 highlights the growing adoption of "agentic AI" platforms that create dynamic digital replicas of clinical research sites, allowing sponsors to simulate feasibility before committing resources. When appropriately validated, prognostic covariate adjustment may improve precision and can support a smaller sample size for a specified endpoint. It remains an analysis method within a randomized trial; it does not eliminate the need for randomized participants or imply that no participant receives placebo or standard therapy. Trial-specific design and analysis plans require regulatory agreement. AI-supported screening may reduce manual review burden, but accuracy, cost, and any effect on trial timelines should be evaluated for the intended population, workflow, and context of use.

• Trial Monitoring and Data Analysis: During a trial, AI tools help manage the deluge of data and enable faster trial completion and readout. Risk-based monitoring systems enhanced with AI continuously analyze incoming data for anomalies or safety signals, rather than relying on infrequent manual checks. This real-time oversight allows sponsors to detect issues (like data entry errors, protocol deviations, or emerging safety concerns) immediately and intervene, potentially helping to prevent costly delays or trial failures ^[3]. AI-driven monitoring proved valuable during the H1N1 pandemic in 2009 and has since evolved to flag cross-site trends and patient-specific risks early ^{[3] [4]}. Another area is automated data cleaning and standardization. Traditionally, after a trial concludes, months may be spent on cleaning datasets, mapping them to regulatory submission standards (like FDA’s SDTM format), and generating analysis outputs (tables, listings, figures). AI greatly accelerates this. Automation may assist data standardization, data-quality review, and preparation of draft study documents, but performance and validation requirements must be assessed for the specific workflow and submission context. AI may assist interim-data review, but early stopping or another adaptation must be prospectively specified in the protocol and statistical analysis plan, preserve trial integrity, and be conducted with appropriate independent oversight. An AI analysis cannot retrospectively make an unplanned early stop scientifically valid. FDA adaptive-design guidance ICH E20 draft guideline Finally, AI is being used to improve patient retention by predicting which enrolled patients might drop out (e.g. based on engagement data or travel distance) and enabling targeted retention strategies – thereby ensuring trials finish on schedule ^[5].

These applications may improve selected trial operations, but a tool's effect on enrollment, monitoring, data quality, or overall trial duration must be demonstrated for its specific context of use. AI does not replace human oversight in trials. Methods such as PROCOVA are trial-specific covariate-adjustment approaches within randomized trials; their use requires an appropriate scientific rationale, validation, and regulatory engagement for the development program. FDA’s draft AI guidance similarly describes a risk-based credibility assessment tailored to an AI model’s defined context of use. EMA qualification materials FDA draft guidance In December 2025, the FDA qualified AIM-NASH, its first AI drug development tool, to help pathologists assess MASH disease activity in clinical trials. Pathologists remain responsible for the final interpretation of the biopsy images and AI-generated scores. With appropriate validation, governance, and human oversight, AI tools may improve selected trial operations; their effect on speed, efficiency, and evidentiary rigor depends on the application and study context. As one FDA representative observed, AI has the potential to "hasten the development of new treatments as well as improve trial design, patient recruitment and selection, [and] safety monitoring", bringing us closer to an era of faster and more patient-centric trials.

After successful clinical trials, a drug sponsor must compile and submit extensive documentation to regulatory agencies (such as the FDA or EMA) to obtain marketing approval. Preparing a New Drug Application (NDA) or Biologics License Application (BLA) is a massive undertaking, involving tens of thousands of pages of data, analysis, and reports from all stages of development. AI is streamlining aspects of the regulatory submission and review process, which traditionally can take a year or more from final data lock to approval.

• Automated Document Generation and Review: AI-driven natural language processing can assist in writing and organizing the common technical document modules required in submissions. For example, generative AI tools can draft clinical study summaries or risk assessments by intelligently summarizing trial results and safety data. This reduces the medical writing burden and ensures consistency across documents. A regulatory technology study noted that machine learning algorithms can cross-check new drug applications against past approvals to ensure all required data and justifications are present. By quickly comparing a draft submission to a library of successful (and failed) applications, AI can flag missing sections, inconsistent data, or potential questions regulators might raise – allowing sponsors to address these before filing. This kind of automated quality control helps avoid time-consuming back-and-forth questions from regulators after submission, thereby shortening the review cycle. Pharmaceutical companies have begun using AI “assistants” in compiling Module 2 summaries (overviews of quality, nonclinical, and clinical findings) and have reported a noticeable reduction in the time needed to produce high-quality drafts ^{[6] [7]}. Additionally, tools for intelligent document tagging and hyperlinking expedite the assembly of electronic submissions by automatically linking supportive evidence throughout the application, a task that otherwise takes significant manual effort.

• Data Standardization and Analysis for Submission: Regulators require that clinical trial datasets be submitted in standardized formats such as CDISC SDTM and ADaM. Automation, including AI-enabled tools, may support data mapping, data-quality review, and preparation of draft analyses or documents. Sponsors remain responsible for the quality and reliability of submitted information, and performance must be validated for the specific data, workflow, and regulatory context.

• Regulatory Review and Decision Support: On the regulatory agency side, AI is also beginning to play a role in expediting approvals. The FDA has recognized the need to harness AI to cope with the growing volume of data in submissions. In January 2025, the FDA released draft guidance – "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products" – involving multiple FDA offices and centers. The guidance introduces a risk-based credibility assessment framework requiring sponsors to: (1) define the regulatory question the AI model addresses, (2) assess model risk based on influence and decision consequence, (3) develop a credibility assessment plan, and (4) document outcomes. Higher-risk AI applications require more rigorous validation, while lower-risk uses may need only basic evidence. As of this draft guidance, FDA was seeking comments and stated that it would consider them before finalizing the recommendations. The FDA has also prototyped internal AI tools (sometimes dubbed "digital reviewers"), which can rapidly sift through submission documents to identify critical information or inconsistencies. For example, an AI might highlight all instances of a certain adverse event across thousands of pages, helping reviewers ensure nothing is overlooked – thereby accelerating the review process. Additionally, health authorities have been modernizing their submission platforms (e.g., adopting cloud-based data portals and AI for data validation) to allow more real-time collaboration with sponsors. The COVID-19 pandemic spurred regulatory agencies to work in parallel with sponsors using shared data environments; this trend, combined with AI, enables rolling reviews and quicker feedback loops. According to industry experts, a "tool-based, digital submission process" featuring AI-based data exchange can significantly reduce processing time and enhance transparency during reviews.

AI may support preparation and review of regulatory information, but it does not itself shorten an approval or substitute for the evidence required for a specific regulatory question. FDA’s January 2025 guidance remains draft, is nonbinding, and describes a risk-based credibility assessment for an AI model’s defined context of use. It does not endorse any particular AI technique or provide blanket acceptance of predicted outcomes, virtual-patient analyses, or manufacturing-quality predictions. FDA draft guidance

Even after a drug is approved, a critical determinant of how fast it reaches patients is the ability to manufacture it at scale with consistent quality. The transition from small-scale clinical manufacturing to full commercial production can be fraught with challenges that cause delays (for example, optimizing a production process, scaling up yield, or meeting Good Manufacturing Practice (GMP) quality specs). AI and digital technologies are now transforming pharmaceutical manufacturing, enabling faster scale-up and more reliable production, which in turn accelerates the time to market availability of new drugs. Key contributions of AI in this domain include:

• Process Optimization and Scale-Up Modeling: Traditionally, developing a scalable manufacturing process for a new drug (whether a chemical synthesis or a biologic cell culture process) involves extensive experimentation – tweaking process parameters, scaling equipment, and analyzing output quality. AI greatly speeds up this optimization. Machine learning models can be trained on process data to understand how factors like temperature, pH, mixing time, or nutrient feeds affect yield and product quality. These models are then used to identify optimal process conditions much faster than trial-and-error lab work. According to the FDA, AI-based models can help “identify optimal process design and scale-up strategies that reduce development time and waste” in drug manufacturing. For example, before scaling a new monoclonal antibody from a 50L pilot reactor to a 2000L production bioreactor, an AI may simulate various conditions to find the best agitation rate and feeding schedule that maximize titer while maintaining product purity. This simulation-guided approach means fewer failed batches and a shorter process development cycle. Some manufacturers use digital twins of their production lines – virtual replicas powered by AI that can predict how a process will behave at larger scale or if a parameter is changed. These digital twins allow engineers to test scale-up scenarios in silico (hours or days of computation) instead of running numerous full-scale test batches (which could take weeks each). As a result, companies can reach a robust, scaled process and GMP readiness sooner. A McKinsey analysis observed that generative AI and other models have the potential to dramatically reduce the time needed to refine manufacturing processes, by learning from prior process data across products. In one case, a model-informed scale-up eliminated several rounds of experimentation, cutting the scale-up time by months while also reducing material waste.

• Automated Control and Real-Time Release: AI is driving the adoption of “smart factories” in pharma, where manufacturing equipment is outfitted with sensors feeding data to AI systems that continuously monitor and adjust the process. This results in more efficient and faster production cycles. For instance, AI-based control systems can adjust conditions on the fly to keep a process within optimal ranges, reducing batch failures and variability. AI and advanced analytics may support process monitoring and control. They do not by themselves authorize real-time release or eliminate required testing: any release strategy must be validated and meet applicable current good manufacturing practice requirements and regulatory expectations. Additionally, AI enhances predictive maintenance of manufacturing equipment – by analyzing sensor data, AI can predict when a machine part might fail or when a cleanup is needed, so maintenance can be done proactively. This minimizes unexpected downtime and keeps production schedules on track. Predictive-maintenance tools may help identify equipment issues earlier, but their operational benefit depends on the product, equipment, implementation, and validated maintenance strategy.

• Quality Control and Compliance: Quality control in pharma is rigorous – every batch must meet specifications and every deviation must be investigated. AI accelerates quality assurance by automating many control steps. For example, AI-powered computer vision systems can inspect tablets or vials on the production line far more quickly and consistently than human inspectors, catching defects in real time. AI-based computer-vision systems may support inspection, but their performance and any effect on inspection throughput must be established through validation for the particular product and process. AI algorithms also help in analyzing process deviations – by mining historical batch data, they can often pinpoint the root cause of an out-of-spec result in hours, whereas a traditional investigation might take days of laboratory work. This rapid resolution of issues means the production line can resume operation faster after a hiccup. Moreover, regulatory compliance is aided by AI-driven record-keeping and data integrity checks. Modern manufacturing execution systems use AI to verify that every step was performed within allowed ranges and flag any data anomalies instantaneously. This reduces the risk of compliance issues that could otherwise force a manufacturing pause or product recall. FDA’s January 2025 draft guidance provides non-binding recommendations for a risk-based credibility assessment of an AI model used to support regulatory decision-making on drug safety, effectiveness, or quality in its defined context of use; it does not provide blanket approval of AI-controlled manufacturing processes. FDA draft guidance The end result is a manufacturing process that not only scales up faster but also is more robust, reducing the likelihood of supply disruptions once the drug is on the market.

Thanks to these innovations, companies can move from pilot production to full-scale market supply in less time. Evidence on manufacturing performance is highly dependent on the product, process, implementation, and validation strategy. A 2025 Hexagon-commissioned survey of 161 manufacturing technology decision-makers at European pharmaceutical companies with at least $1 billion in annual revenue found that 65% identified AI for predictive maintenance as an investment priority for the following 12 months; it did not report an average throughput increase. Hexagon survey Process analytical technology and continuous manufacturing can support process understanding and control, but performance metrics should be assessed for the specific product, process, and validated control strategy. The industry's trajectory toward smart factories and "Pharma 4.0" is accelerating, with manufacturers planning significant investments in IoT sensors, advanced robotics, and cloud infrastructure to support AI-driven manufacturing at scale. In summary, AI in manufacturing ensures that once a drug is approved, the supply chain can keep pace with urgency – enabling patients to get the treatment sooner and reducing backlogs or rationing of new medicines. As the PDA (Parenteral Drug Association) concluded in a recent workshop, the integration of AI from raw material handling to production control yields a host of benefits: "speed to production, continuous optimization, faster turnover, and scale-up capacity" are all enhanced, ultimately supporting a quicker launch and broader patient access.

The biopharma industry has embraced AI across a spectrum of applications, and several notable case studies illustrate its impact on development timelines:

• Insilico Medicine – Rentosertib Phase IIa Study: Rentosertib (formerly ISM001-055) is an AI-generated TNIK inhibitor for idiopathic pulmonary fibrosis. Its 71-participant, 12-week, randomized, placebo-controlled Phase IIa study had treatment-emergent adverse events as its primary endpoint. The highest-dose group had a positive secondary FVC signal, but 16 participants discontinued treatment before week 12; seven discontinuations for adverse events were due to liver injury or dysfunction. The authors concluded that larger and longer studies are needed. The study is important early clinical evidence for an AI-generated candidate; it does not establish efficacy or demonstrate that AI-found drugs generally progress faster. Study details

• Recursion–Exscientia – DSP-1181 exploratory-research project: Sumitomo Dainippon Pharma and Exscientia announced in January 2020 that a Phase I study of DSP-1181 for obsessive-compulsive disorder had begun in Japan. The companies said their joint exploratory-research phase took less than 12 months, compared with a cited conventional-research average of 4.5 years. This is a company-stated benchmark for that exploratory-research project, not a measure of time from project start to Phase I entry or a general platform-wide reduction in design time. Sumitomo Pharma announcement In a transformative industry move, Recursion Pharmaceuticals acquired Exscientia in late 2024 for $688 million, creating a vertically integrated AI drug discovery platform that combines Recursion's phenomic screening with Exscientia's automated precision chemistry. The combined entity has received over $450 million in upfront and realized milestone payments from partners, with more than $20 billion in potential pipeline value. Key clinical programs under the merged company include REC-394 (C. difficile inhibitor, Phase 2 update expected Q1 2026) and REC-1245 (RBM39 degrader, Phase 1 data expected H1 2026). The company has also streamlined its portfolio, deprioritizing several programs to focus resources on oncology and rare diseases with the strongest scientific rationale – a sign of AI-driven portfolio discipline rather than "spray and pray" development.

• BenevolentAI – Rapid Drug Repurposing and Cautionary Lessons: Beyond de novo drug design, AI also shines in drug repurposing. In early 2020, UK-based BenevolentAI applied its AI knowledge graph system to identify existing approved drugs that might inhibit the COVID-19 virus. In a matter of days, their AI sifted through vast biomedical databases and pinpointed baricitinib, a rheumatoid arthritis drug, as a promising COVID-19 treatment due to its anti-inflammatory and antiviral properties. This was published in The Lancet in February 2020, and subsequently baricitinib was tested in clinical trials for COVID-19. By late 2020 it received Emergency Use Authorization and later full approval as a COVID-19 therapy – an extraordinarily fast turnaround from hypothesis to patient use. However, BenevolentAI's trajectory also illustrates the challenges facing AI drug companies: in 2023, its lead AI-derived candidate BEN-2293 failed to show efficacy in a Phase IIa trial for eczema, becoming one of the first high-profile AI drug failures. The company subsequently underwent significant restructuring, laying off 30% of staff and exiting its US site. In early 2025, BenevolentAI completed a reverse merger with Osaka Holdings and continues to advance pipeline candidates including BEN-8744 (PDE10 inhibitor for ulcerative colitis) and BEN-28010 (for glioblastoma). The case exemplifies both AI's ability to respond to emerging health threats quickly and the reality that AI-accelerated discovery still faces the same clinical attrition challenges as traditional drug development.

• Atomwise (AtomNet) – Faster Lead Discovery: Atomwise is a company using deep learning (their AtomNet model) for structure-based drug design. In a collaboration with IBM and researchers, AtomNet was used to screen millions of molecules in silico for new Ebola virus inhibitors – a task completed in just a few weeks, after which top candidates were tested and found to have activity. Such an approach can compress what might be a multi-year screening project into a few months. Atomwise has partnerships with large pharma companies to rapidly identify preclinical leads for targets in CNS and oncology, often finding viable hits 5–10 times faster than traditional high-throughput wet lab screening. In 2024–2025, the company raised a $125 million Series C round (bringing total funding to $219 million) and appointed pharmaceutical industry veteran Steve Worland as CEO to drive its pipeline programs toward clinical stages. These leads then enter the usual testing pipeline, but the initial time to a lead compound is shortened significantly.

• Clinical Trial AI Platforms – Trial Accelerators: Several platform solutions have emerged to help pharma run faster trials. Microsoft's AI for Health partnership with Novartis built AI models to predict clinical trial outcomes and identify optimal trial designs – these have been credited with reducing protocol design timelines at Novartis and improving their ability to launch trials faster^{[8] [9]}. On the startup side, Unlearn.AI develops prognostic-covariate and digital-twin tools for randomized trials. EMA published a 2022 qualification opinion for PROCOVA™: it uses predicted placebo outcomes (prognostic scores), generated from historical data, in linear covariate adjustment to improve the efficiency of Phase 2 and 3 clinical trials. This does not establish a general Phase 2/3 authorization or FDA concurrence. Any proposed use requires trial-specific scientific and regulatory assessment. Sanofi has also embraced digital twinning at scale across its clinical portfolio, using AI-generated patient predictions to optimize trial designs. Meanwhile, Accenture's December 2025 investment in Ryght AI signals the emergence of "agentic AI" – autonomous AI systems that create dynamic digital replicas of entire clinical research sites, allowing sponsors to simulate site feasibility before contracts are signed. These case studies show that AI tools are being evaluated and deployed in trial operations, while their utility and regulatory acceptability remain dependent on the specific application and supporting evidence.

AI is being applied across discovery, clinical development, and manufacturing, but aggregate counts of “AI-originated” programs and predictions of first approvals depend on definitions and proprietary datasets. FDA’s current drug-and-biological-products AI guidance remains a January 2025 draft, with non-binding recommendations for a risk-based credibility assessment tailored to an AI model’s context of use. FDA and EMA also describe good AI practice as human-centric, risk-based, and supported by appropriate data governance, performance assessment, and life-cycle management. These principles are more informative than unsupported forecasts when assessing whether an AI application can contribute credible evidence in a particular development program.

Speeding up the pipeline from discovery to patient access is not just a win for industry – it carries profound public health benefits. When life-saving treatments reach the market faster, patients and healthcare systems see tangible improvements:

• Faster Access to Life-Saving Treatments: Perhaps the most obvious benefit is that patients receive effective new therapies sooner. For someone with a serious or terminal illness, even a reduction of a year or two in drug development can be the difference between having or missing a treatment in their lifetime. A health-economics analysis of illustrative treatments for advanced malignancies estimated a median 79,920 potential life-years gained worldwide per year of acceleration. That modeled estimate assumed that all relevant patients received the treatment and that trial results reflected real-world outcomes; it should not be presented as a general result for every drug. Delays can be devastating – one ISPOR study found that in Canada, delays in access to new cancer drugs cost 6,400 patients about 1,740 life-years and 1,122 quality-adjusted life years (QALYs), alongside significant suffering. The worst delays (seen in some countries with ~15-year lags in adopting new therapies) were estimated to reduce survival by 5.7 life-years per patient in certain cases. Thus, accelerating development directly translates to lives saved and improved quality of life, especially in areas like oncology, rare genetic diseases, and other conditions where no adequate treatments exist. For example, the swift development of immune checkpoint inhibitors in the 2010s (a process aided by data science accelerating clinical decisions) has led to markedly improved survival in melanoma and lung cancer, and earlier availability meant thousands of patients who would not have survived lived to see remission. The societal value of these earlier treatments is immense – one study valued the life-years saved by early drug availability in the range of $38,000 to over $1,000,000 per patient per month (depending on the drug and disease severity). In short, time isn’t just money in drug development; time is lives.

• Potential Effects on Costs and Health Systems: More efficient development could reduce some operational burden for a particular program, but it does not establish lower medicine prices, lower health-system spending, or lower attrition across programs. Any economic or clinical benefit should be assessed using study-specific assumptions about the intervention, population, access, pricing, and comparator.

• Improved Patient Outcomes and Public Health: Beyond raw survival, getting drugs to patients sooner improves many outcome measures – patients have better quality of life, fewer disease complications, and families experience less uncertainty. For chronic conditions, an earlier therapy might prevent progression to disability. For acute diseases, lives are saved. Faster development also allows more overlap in successive innovations. For example, if Drug A is approved 2 years faster, researchers can start building on Drug A (through combinations or improvements) that much sooner, accelerating next-generation improvements. This compounding effect can raise the trajectory of medical progress. We saw this with HIV in the 1990s: quicker trials and approvals (helped by surrogate endpoints and strong data management) enabled rapid iteration of drug “cocktails,” turning HIV from a death sentence into a manageable condition in just a few years. On a population level, sooner access can reduce disease prevalence or transmission. A tuberculosis or hepatitis drug reaching the market earlier can reduce the infectious reservoir in the population, yielding public health gains. Faster availability of vaccines is another clear example – an effective vaccine introduced even months earlier can prevent thousands of cases. Notably, in the realm of antibiotic resistance, AI is helping to discover new antibiotics much faster than before. The 2020 AI-identified antibiotic halicin was followed by additional AI-discovered classes, including abaucin (targeting A. baumannii) and candidates from MIT's AI-powered screening platforms. These AI-accelerated antibiotic programs, if brought to market quickly, could curb the rise of resistant infections and save countless lives that would be lost to untreatable infections.

• Responsiveness to Emerging Health Threats: COVID-19 vaccine development illustrates how prior research, rapid access to the viral genome, an established mRNA platform, substantial investment, and overlapping development activities can shorten timelines without omitting the evidence required for authorization. The NIH–Moderna vaccine received FDA emergency-use authorization on December 18, 2020. WHO reported a modeled estimate of 19.8 million lives saved globally in the first year of COVID-19 vaccine rollouts. These findings should not be attributed to AI: NIH's account of the NIH–Moderna vaccine does not identify AI as a material cause of its initial timeline. AI may assist future countermeasure research, but its contribution to a particular product timeline requires direct evidence. NIH account WHO estimate

• Economic and Healthcare System Resilience: Faster drug development can also strengthen health systems. When effective drugs are available sooner, healthcare providers can more quickly adopt the best standards of care, improving overall population health. Moreover, the knowledge that development timelines are shorter may encourage pharmaceutical investment in areas of unmet need (including rare diseases or emerging infectious diseases) because the path to return on investment is quicker and more certain. This could lead to a virtuous cycle where more conditions have therapies being developed, further benefiting public health. From an economic standpoint, high development costs and long timelines are often cited as reasons for high drug prices; reducing these factors could alleviate some pressure on healthcare budgets. Additionally, when new therapies reduce disease burden earlier, that can lower long-term healthcare costs (for example, curing a disease now prevents decades of chronic treatment expenses). Faster access also means health systems can plan better – during COVID, for instance, knowing that vaccines were on the near horizon (thanks to accelerated trials) allowed governments to strategize vaccination campaigns and allocate resources, as opposed to facing an open-ended crisis. In less acute scenarios, if an Alzheimer’s drug is coming 3–4 years earlier than expected, healthcare systems can prepare infrastructure (like diagnostic services) to deliver it effectively, amplifying its benefits.

In conclusion, AI and related digital tools may support parts of drug discovery, development, and manufacturing when they are fit for their defined use and supported by appropriate validation, governance, and human oversight. Whether a tool improves a program's timeline, cost, attrition, regulatory evidence, or patient outcomes must be established for that application; speed cannot substitute for rigorous evidence of safety, effectiveness, and quality.

Sources: This report drew on evidence from peer-reviewed journals, regulatory agency publications, and leading industry analyses. Key references include Nature, Nature Medicine, npj Digital Medicine, Alzheimer's & Dementia, and Lancet studies on AI's impact; FDA guidance documents and commentary on AI in drug development; reports by BCG-Wellcome, McKinsey, and others quantifying AI-driven efficiencies; and case study disclosures from biopharma companies like Insilico Medicine, Recursion–Exscientia, and Novartis. Additional sources include the World Economic Forum's 2026 analysis of AI in drug discovery, Drug Target Review's 2025 year-in-review, and Applied Clinical Trials' 2026 outlook. These sources, as cited throughout, collectively demonstrate both the current achievements and future potential of AI to accelerate each stage of bringing a drug to market – ultimately to the benefit of patients and society at large.